​

Aurinia Pharmaceuticals Stock (NASDAQ:AUPH)

ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$7.75

52W Range

$4.71 - $10.67

50D Avg

$8.03

200D Avg

$7.49

Market Cap

$1.05B

Avg Vol (3M)

$1.41M

Beta

1.22

Div Yield

-

AUPH Company Profile

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

130

IPO Date

Sep 03, 2014

Website

AUPH Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 23Dec 22
License, Collaboration and Royalty Revenue$18.95M$16.98M-
Product$216.19M$158.53M$103.47M
License--$30.56M

Fiscal year ends in Dec 24 | Currency in USD

AUPH Financial Summary

Dec 24Dec 23Dec 22
Revenue$235.13M$175.51M$134.03M
Operating Income$-4.69M$-91.69M$-111.47M
Net Income$5.75M$-78.02M$-108.18M
EBITDA$-4.69M$-63.05M$-103.65M
Basic EPS$0.04$-0.54$-0.76
Diluted EPS$0.04$-0.54$-0.76

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q4 24Feb 27, 25 | 8:30 AM
Q3 24Nov 07, 24 | 8:30 AM
Q2 24Aug 01, 24 | 8:30 AM

Peer Comparison

TickerCompany
AXSMAxsome Therapeutics, Inc.
HEPAHepion Pharmaceuticals, Inc.
TERNTerns Pharmaceuticals, Inc.
SRPTSarepta Therapeutics, Inc.
VKTXViking Therapeutics, Inc.
PTCTPTC Therapeutics, Inc.
EXELExelixis, Inc.
BTAIBioXcel Therapeutics, Inc.
AKROAkero Therapeutics, Inc.
MCRBSeres Therapeutics, Inc.
TGTXTG Therapeutics, Inc.
MDGLMadrigal Pharmaceuticals, Inc.